What are the clinical features, diagnostic criteria, and management of paramyotonia congenita?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Paramyotonia Congenita: Clinical Features, Diagnosis, and Management

Overview and Pathophysiology

Paramyotonia congenita is an autosomal dominant skeletal muscle sodium channelopathy caused by missense mutations in the SCN4A gene, which encodes the α subunit (NaV1.4) of the voltage-gated sodium channel, resulting in cold-induced myotonia and episodic weakness that paradoxically worsens with continued muscle activity. 1, 2

Clinical Features

Characteristic Symptoms

  • Cold-induced muscle stiffness (myotonia) affecting primarily the eyelids, hands, face, and jaw, which paradoxically worsens with repeated muscle contraction rather than improving (the "paradoxical" feature distinguishing it from other myotonias) 3

  • Episodic weakness triggered by cold exposure and exercise, though some patients present with stiffness alone without weakness episodes 4

  • Symptom onset in childhood, typically manifesting in early years with lifelong persistence but non-progressive course 3

  • Temperature sensitivity as the defining feature, with symptoms provoked by cold exposure (cold water immersion, cold weather) and improving with warming 2, 5

Distribution Pattern

  • Predominantly affects distal muscles initially (hands, eyelids) before potentially involving proximal limb muscles 3

  • Facial muscles including eyelids and jaw muscles are characteristically involved 3, 4

Diagnosis

Clinical Examination

  • Percussion myotonia at the thenar eminence is typically demonstrable on physical examination 3

  • Family history revealing autosomal dominant inheritance pattern supports the diagnosis 3

Electrophysiological Testing

  • Electromyography (EMG) shows generalized myotonic discharges with characteristic high-frequency runs 3

  • Short exercise test following cold exposure demonstrates a pathognomonic decrease in compound motor action potential (CMAP) amplitude after exercise, even in patients without clinical weakness episodes 4

  • Repetitive nerve stimulation after ice bath immersion reveals a decrement pattern that confirms the diagnosis 4

Molecular Genetic Testing

  • Direct DNA sequencing of the SCN4A gene is the definitive diagnostic test, identifying specific missense mutations 1, 2

  • Most common mutations occur at position T1313 (threonine to methionine or alanine) in the DIII-DIV cytoplasmic loop, and at R1448 (arginine to cysteine, histidine, proline, or serine) in the DIV-S4 segment 1, 3, 5

  • The DIII-DIV cytoplasmic loop is the critical region that pivots during membrane depolarization to inactivate the channel; mutations here disrupt fast inactivation, causing persistent sodium current and membrane hyperexcitability 1

Functional Consequences of Mutations

  • Mutations cause gain-of-function changes with impaired fast inactivation: slowed kinetics, reduced voltage sensitivity, accelerated recovery from inactivation, and temperature-sensitive alterations 2, 5

  • At cold temperatures, mutant channels show hyperpolarizing shift in activation and depolarizing shift in fast inactivation, creating a window for persistent sodium current that triggers myotonia 2, 5

Treatment

Preventive Measures

  • Avoid cold exposure as the primary management strategy, including cold water, cold weather, and air conditioning 3

  • Precautions during general anesthesia are essential due to risk of diaphragm myotonia and respiratory complications 3

Pharmacological Management

  • Mexiletine (membrane-stabilizing antiarrhythmic agent) is the first-line medication, demonstrating objective improvement in both clinical symptoms and electrophysiological abnormalities on short exercise testing 4

  • Tocainide (another membrane-stabilizing antiarrhythmic) can be used as an alternative 3

  • Acetazolamide (carbonic anhydrase inhibitor) may be beneficial in some patients, though evidence is less robust than for mexiletine 3

Prognosis

  • Non-progressive disorder with stable symptoms throughout life, distinguishing it from degenerative neuromuscular diseases 3

  • No cardiac involvement is expected, unlike myotonic dystrophy, as paramyotonia congenita affects only skeletal muscle sodium channels 3

  • Quality of life can be significantly improved with appropriate cold avoidance and mexiletine therapy when symptoms are bothersome 4

Key Clinical Pitfalls

  • Do not confuse with myotonic dystrophy, which has multisystem involvement including cardiac conduction defects, cataracts, and progressive weakness—paramyotonia congenita is purely a skeletal muscle disorder 3

  • The paradoxical worsening with exercise (rather than warm-up phenomenon) is pathognomonic and distinguishes paramyotonia from myotonia congenita 3

  • Genetic testing is essential for definitive diagnosis and genetic counseling, as clinical overlap exists among sodium channelopathies 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.